121 128
Figure 4. Hematopoietic Cells Derived from MDS/AML-iPSCs Give Rise to Serially Transplantable Leukemia
(A) Scheme of transplantation experiments. Various iPSC lines were differentiated along the hematopoietic lineage for 8–16 days, as shown in Figure 2A and
intravenously injected into sub-lethally irradiated or busulfan-treated NSG mice.
(B) Representative flow cytometry panels assessing human cell engraftment in the bone marrow of recipient mice 8–11 weeks post-transplantation.
(C) Engraftment levels in the bone marrow of mice 8–11 weeks after transplantation with HPCs derived from different iPSC lines (normal: N-2.12; low-risk MDS:
MDS-1.12; high-risk MDS: MDS-2.13) or with human cord blood CD34
+
cells (CB). Error bars show the mean and SEM.
Each data point represents a unique mouse from five independent transplantation experiments.
(D) Fraction of myeloid (CD33
+
) and lymphoid (CD19
+
) lineage cells within the hCD45
+
population in the BM of mice transplanted with human cord blood CD34
+
cells (CB) or MDS/AML-iPSC-derived hematopoietic cells (from lines AML-4.24 and AML-4.10) 8–11 weeks after transplantation. CB engraftment typically gives
(legend continued on next page)
Cell Stem Cell
20
, 315–328, March 2, 2017
321